At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
AKST1210 +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Phase 2a Study to Evaluate the Tolerability, Feasibility, and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment Associated With End-Stage Renal Disease
In Brief
A clinical study evaluating AKST1210, Sham Control (No Intervention), and 1 other intervention for Cognitive Impairment and End Stage Renal Disease. Completed, enrolled 10 participants across 4 sites.
Detailed Summary
This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognitive Impairment, End Stage Renal Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedAug 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedAug 26, 2020
Enrollment StartApr 28, 2020
Primary CompletionJun 4, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.9 years ago
Interventions
AKST1210device
AKST1210
Sham Control (No Intervention)other
A covered surrogate object of similar size and shape as the investigational device
Hemodialysisprocedure
Hemodialysis